Gilead Sciences (GILD) 101.81 $GILD
Genfit: Pivotal Phase IIb Data On NASH Offers High Risk/Reward Trade
Arthur Jeannerot - at Seeking Alpha - Sat Mar 07, 6:37AM CST
SAN: 6.98 (-0.21), GILD: 101.81 (-1.61), ICPT: 266.14 (+4.96), SNY: 47.42 (-0.94)
Forget Gilead Sciences (GILD), Buy These Biotech Stocks Instead - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Fri Mar 06, 8:15PM CST
Gilead Sciences (GILD) has had a nice run but it is time to look to other options in the biotech world, such as the stocks listed in this article.
CBM: 33.77 (-0.63), GILD: 101.81 (-1.61), THRX: 19.60 (-0.26), AFFX: 11.81 (-0.38)
Final Glance: Biotechnology companies
AP - Fri Mar 06, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), CELG: 118.03 (-2.68)
Midday Glance: Biotechnology companies
AP - Fri Mar 06, 12:25PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), CELG: 118.03 (-2.68)
Gilead, Mylan, And J&J: Cheap Compared To Peers
Hedgephone - at Seeking Alpha - Fri Mar 06, 11:32AM CST
JNJ: 100.11 (-2.41), GILD: 101.81 (-1.61), IBB: 342.36 (-5.31), MYL: 55.44 (-1.25)
Early Glance: Biotechnology companies
AP - Fri Mar 06, 9:57AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), CELG: 118.03 (-2.68)
Stock Market News for March 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:10AM CST
Markets snapped a two-day losing streak on Thursday, somewhat boosted by the ECB announcing a trillion-dollar stimulus plan that will kick off on Monday
BIIB: 417.63 (-7.98), JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), ADP: 86.00 (-0.75), MDT: 76.48 (-2.02), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93)
2 Stock Bargains 'Hiding' In Plain Sight
Hawkinvest - at Seeking Alpha - Fri Mar 06, 6:53AM CST
GILD: 101.81 (-1.61), GNW: 7.67 (+0.06)
5 Toxic Stocks to Sell in March: Vodafone, Berkshire and More
at The Street - Fri Mar 06, 6:00AM CST
It's time to unload these stocks from your portfolio.
T: 33.48 (-0.52), GILD: 101.81 (-1.61), TROX: 19.61 (-0.49), BRK.B: 145.28 (-0.78), VOD: 32.97 (-1.40)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 4.61 (-0.19), GLMD: 9.29 (-0.33), PTBI: 3.50 (-0.05), CNAT: 6.05 (-0.54), GALT: 3.71 (+0.02), SRNE: 13.63 (+0.03), CELG: 118.03 (-2.68), GILD: 101.81 (-1.61), KITE: 66.41 (+1.44), CFRX: 4.61 (+0.28), ICPT: 266.14 (+4.96), JUNO: 52.84 (+0.81), CORT: 3.42 (-0.19)
Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 3:45PM CST
Bristol-Myers Squibb announced encouraging data from a phase III study evaluating a once-daily combination of Daklinza and Gilead Sciences Inc.'s Sovaldi.
GILD: 101.81 (-1.61), CLDX: 29.39 (-0.39), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93)
Where To Put My Money: Another Look At My Core Holdings
Investing Doc - at Seeking Alpha - Thu Mar 05, 2:18PM CST
JNJ: 100.11 (-2.41), ESRX: 82.27 (-2.01), VAR: 93.18 (-1.04), TJX: 68.03 (-0.69), MON: 118.17 (-1.10), GILD: 101.81 (-1.61), BAX: 67.73 (-1.48), UL: 43.02 (-1.26), PG: 82.66 (-1.97), AAPL: 126.60 (+0.19), SLB: 83.11 (-1.71), PCLN: 1,215.99 (-15.91)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), GPRO: 40.13 (-0.95), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), KMB: 106.82 (-1.64), LLTC: 47.65 (-0.72), BMY: 65.12 (-0.93), ALKS: 68.19 (-3.03), CHRS: 27.48 (-2.23), CELG: 118.03 (-2.68), W: 28.81 (+1.03), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), LH: 121.70 (-1.58), MCD: 97.13 (-1.98), REGN: 422.13 (-6.82), BABA: 84.40 (-1.70)
Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More
at The Street - Thu Mar 05, 4:34AM CST
Cramer says that Honeywell is his one of his favorite industrial stocks and that the biotech sector is filled with strong buys, including Regeneron and Celgene.
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), W: 28.81 (+1.03), HON: 101.87 (-1.26), GILD: 101.81 (-1.61), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
AbbVie Will Buy Pharmacyclics For $21 Billion
at Investor's Business Daily - Thu Mar 05, 1:54AM CST
AbbVie is making a major oncology push, agreeing late Wednesday to pay $21 billion to acquire Pharmacyclics (PCYC), maker of blockbuster blood cancer drug Imbruvica. AbbVie will pay $261.25 per share in cash and stock. That's 13% above Pharmacyclics'...
JNJ: 100.11 (-2.41), ESRX: 82.27 (-2.01), PCYC: 254.56 (+0.34), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93), NVS: 97.46 (-1.49)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), HON: 101.87 (-1.26), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), JNJ: 100.11 (-2.41), W: 28.81 (+1.03), SCTY: 50.45 (-1.32), CMG: 658.68 (-11.81), RCPT: 140.09 (-1.10), FL: 59.37 (+2.34), REGN: 422.13 (-6.82), HYH: 46.26 (+0.79), CY: 15.10 (-0.40), SWKS: 90.75 (-0.80), VFC: 74.49 (-1.58), NXPI: 98.48 (-0.19), ALKS: 68.19 (-3.03), CELG: 118.03 (-2.68), WWAV: 41.79 (-0.63), URBN: 38.89 (+0.15), HAIN: 61.66 (-1.03), FSLR: 60.61 (-1.05), GOGO: 20.21 (+0.14), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), MCD: 97.13 (-1.98), STM: 9.18 (-0.13), DST: 106.03 (+0.16), BIG: 48.52 (+0.70), AVGO: 127.89 (-2.68)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 7.10 (-0.91), VRTX: 126.34 (-0.62), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), ARNA: 4.32 (+0.09), CELG: 118.03 (-2.68)
Genfit: Pivotal Phase IIb Data On NASH Offers High Risk/Reward Trade
Arthur Jeannerot - at Seeking Alpha - Sat Mar 07, 6:37AM CST
SAN: 6.98 (-0.21), GILD: 101.81 (-1.61), ICPT: 266.14 (+4.96), SNY: 47.42 (-0.94)
Forget Gilead Sciences (GILD), Buy These Biotech Stocks Instead - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Fri Mar 06, 8:15PM CST
Gilead Sciences (GILD) has had a nice run but it is time to look to other options in the biotech world, such as the stocks listed in this article.
CBM: 33.77 (-0.63), GILD: 101.81 (-1.61), THRX: 19.60 (-0.26), AFFX: 11.81 (-0.38)
Final Glance: Biotechnology companies
AP - Fri Mar 06, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), CELG: 118.03 (-2.68)
Midday Glance: Biotechnology companies
AP - Fri Mar 06, 12:25PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), CELG: 118.03 (-2.68)
Gilead, Mylan, And J&J: Cheap Compared To Peers
Hedgephone - at Seeking Alpha - Fri Mar 06, 11:32AM CST
JNJ: 100.11 (-2.41), GILD: 101.81 (-1.61), IBB: 342.36 (-5.31), MYL: 55.44 (-1.25)
Early Glance: Biotechnology companies
AP - Fri Mar 06, 9:57AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), CELG: 118.03 (-2.68)
Stock Market News for March 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:10AM CST
Markets snapped a two-day losing streak on Thursday, somewhat boosted by the ECB announcing a trillion-dollar stimulus plan that will kick off on Monday
BIIB: 417.63 (-7.98), JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), ADP: 86.00 (-0.75), MDT: 76.48 (-2.02), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93)
2 Stock Bargains 'Hiding' In Plain Sight
Hawkinvest - at Seeking Alpha - Fri Mar 06, 6:53AM CST
GILD: 101.81 (-1.61), GNW: 7.67 (+0.06)
5 Toxic Stocks to Sell in March: Vodafone, Berkshire and More
at The Street - Fri Mar 06, 6:00AM CST
It's time to unload these stocks from your portfolio.
T: 33.48 (-0.52), GILD: 101.81 (-1.61), TROX: 19.61 (-0.49), BRK.B: 145.28 (-0.78), VOD: 32.97 (-1.40)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 4.61 (-0.19), GLMD: 9.29 (-0.33), PTBI: 3.50 (-0.05), CNAT: 6.05 (-0.54), GALT: 3.71 (+0.02), SRNE: 13.63 (+0.03), CELG: 118.03 (-2.68), GILD: 101.81 (-1.61), KITE: 66.41 (+1.44), CFRX: 4.61 (+0.28), ICPT: 266.14 (+4.96), JUNO: 52.84 (+0.81), CORT: 3.42 (-0.19)
Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 3:45PM CST
Bristol-Myers Squibb announced encouraging data from a phase III study evaluating a once-daily combination of Daklinza and Gilead Sciences Inc.'s Sovaldi.
GILD: 101.81 (-1.61), CLDX: 29.39 (-0.39), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93)
Where To Put My Money: Another Look At My Core Holdings
Investing Doc - at Seeking Alpha - Thu Mar 05, 2:18PM CST
JNJ: 100.11 (-2.41), ESRX: 82.27 (-2.01), VAR: 93.18 (-1.04), TJX: 68.03 (-0.69), MON: 118.17 (-1.10), GILD: 101.81 (-1.61), BAX: 67.73 (-1.48), UL: 43.02 (-1.26), PG: 82.66 (-1.97), AAPL: 126.60 (+0.19), SLB: 83.11 (-1.71), PCLN: 1,215.99 (-15.91)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), GPRO: 40.13 (-0.95), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), KMB: 106.82 (-1.64), LLTC: 47.65 (-0.72), BMY: 65.12 (-0.93), ALKS: 68.19 (-3.03), CHRS: 27.48 (-2.23), CELG: 118.03 (-2.68), W: 28.81 (+1.03), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), LH: 121.70 (-1.58), MCD: 97.13 (-1.98), REGN: 422.13 (-6.82), BABA: 84.40 (-1.70)
Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More
at The Street - Thu Mar 05, 4:34AM CST
Cramer says that Honeywell is his one of his favorite industrial stocks and that the biotech sector is filled with strong buys, including Regeneron and Celgene.
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), W: 28.81 (+1.03), HON: 101.87 (-1.26), GILD: 101.81 (-1.61), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
AbbVie Will Buy Pharmacyclics For $21 Billion
at Investor's Business Daily - Thu Mar 05, 1:54AM CST
AbbVie is making a major oncology push, agreeing late Wednesday to pay $21 billion to acquire Pharmacyclics (PCYC), maker of blockbuster blood cancer drug Imbruvica. AbbVie will pay $261.25 per share in cash and stock. That's 13% above Pharmacyclics'...
JNJ: 100.11 (-2.41), ESRX: 82.27 (-2.01), PCYC: 254.56 (+0.34), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93), NVS: 97.46 (-1.49)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), HON: 101.87 (-1.26), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), JNJ: 100.11 (-2.41), W: 28.81 (+1.03), SCTY: 50.45 (-1.32), CMG: 658.68 (-11.81), RCPT: 140.09 (-1.10), FL: 59.37 (+2.34), REGN: 422.13 (-6.82), HYH: 46.26 (+0.79), CY: 15.10 (-0.40), SWKS: 90.75 (-0.80), VFC: 74.49 (-1.58), NXPI: 98.48 (-0.19), ALKS: 68.19 (-3.03), CELG: 118.03 (-2.68), WWAV: 41.79 (-0.63), URBN: 38.89 (+0.15), HAIN: 61.66 (-1.03), FSLR: 60.61 (-1.05), GOGO: 20.21 (+0.14), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), MCD: 97.13 (-1.98), STM: 9.18 (-0.13), DST: 106.03 (+0.16), BIG: 48.52 (+0.70), AVGO: 127.89 (-2.68)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 7.10 (-0.91), VRTX: 126.34 (-0.62), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), AMGN: 154.88 (-4.72), ARNA: 4.32 (+0.09), CELG: 118.03 (-2.68)
